http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
유산균들의 콜레스테를 저하성, 내산성, 내담즙성, 항생제 내성 비교
박소영,고영태,정후길,양진오,정현서,김영배,지근억 한국미생물생명공학회 ( 구 한국산업미생물학회 ) 1996 한국미생물·생명공학회지 Vol.24 No.3
기능성 요구르트의 제조에 사용되는 유산균은 인체에 유익한 생리활성과 우수한 생존능력을 보유하고 있는 것이 바람직하다. 본 연구에서는 다양한 유산균주의 산과 담즙 및 항생제에 대한 내성을 조사하였으며 in vitro에서 콜레스테롤 저하능을 조사하였다. In vitro에서 콜레스테롤 저하능이 우수한 13균주를 선발하여 이들의 동결건조 분말을 고 콜레스테롤 식이의 실험쥐에 투여하였다. 그 결과 8균주는 비 투여구보다 유의적으로 18.3~27.3%의 콜레스테롤 저하능을 나타냈다(P≤0.05). 이들 중에서 Bifidobacterium infantis AM-220, Lactobacillus AM-245, Streptococcus MA-1의 3균주를 이용하여 요구르트를 제조한 후 동결건조 분말을 이용하여 급여실험을 수행한 결과, 총 콜레스테롤과 LDL 함량이 유의적으로 감소하는 것으로 나타났다. For a probiotic yoghurt it is desirable to utilize lactic acid bacteria with a high survival rate and beneficial function to human beings. We have examined a variety of lactic acid bacteria to assess the acid and bile tolerance and antibiotic resistance. In addition, an in vitro culture experiment was performed to evaluate their ability to reduce cholesterol levels in the growth medium. Thirteen strains were selected from in vitro cholesterol assays and fed to Sprague-Dawley rats with a high-cholesterol diet. Among the 13 strains tested, 8 strains were shown to reduce serum cholesterol levels significantly after 24 days of administration in vivo. Rats were fed lyophilized yoghurt powder fermented with a combination of 3 selected strains: Bifidobacterium infantis AM-220, Lactobacillus AM-245, and Streptococcus MA-1. The levels of total cholesterol and low density lipoprotein were significantly lower (p≤0.05) in rats fed the yoghurt powder compared with control group. These studies suggest that yoghurt fermented with appropriately selected lactic acid bacteria may have a anticholesterolemic effect.
Isolation of Amylolytic Bifidobacterium sp. Int-57 and Characterization of Amylase
JI, GEUN EOG,HAN, HEE KYUNG,YUN, SEONG WOOK,RHIM, SEONG LYUL 한국미생물 · 생명공학회 1992 Journal of microbiology and biotechnology Vol.2 No.2
The intestinal microflora of humans is an extraordinarily complex mixture of microorganisms, the majority of which are anaerobic microorganisms. The distribution of amylolytic microorganisms in the human large intestinal tract was investigated in various individuals of differing ages using anaerobic culture techniques. A large percentage of the amylolytic microorganisms present belonged to the Genus Bifidobacteria. The number of Bifidobacteria increased significantly at two years of age. Adults and children above 2 years old carried about 0.8×10 exp (9)-2.0×10 exp (10) colony forming units (CFU/gram) of amylolytic Bifidobacteria. Among these amylolytic Biffdobacteria, Int-57 was chosen for further studies. Between 65% and 85% of the amylase produced was secreted and the remaining amylase was bound to the cell wall facing the outside . Amylase production could be induced by starch in a stable form. When cells were grown on maltose or glucose, amylase production was much lower than on starch and amylase activity disappeared after 24 hours growth on these media. Partially purified enzymes showed optimum activity at a temperature of 50℃ and at an optimum pH of 5.5, respectively. Heat treatment at 70℃ for 30 minutes almost completely inactivated amylase. The hydrolysis products of starch were mainly maltose and maltotriose. Soluble starch, amylose, amylopectin, and γ-cyclodextrin(γ-CD) were easily hydrolyzed. The rate of hydrolysis of α-CD and β-CD was slower than that of γ-CD. Carboxymethyl cellulose, β-1,3-glucan and inulin were not hydrolyzed.
Ji, Geun Eog,Paek, Kwang Hyeon 한국산업미생물학회 1992 한국미생물·생명공학회지 Vol.20 No.3
요로계 감염에 대처함에 있어 hemolysin과 Gal-Gal pili의 multicomponent 백신 개발 가능성을 조사하기 위하여 본 연구를 수행하였다. 요로계 감염 환자로부터 분리되어 그의 hemolysin gene의 염기배열과 아미노산 배열이 밝혀진 대장균 J96 균주의 homelysin에 대하여 10곳에 해당하는 20mer-oligonucleotide를 합성하였다. 이들 probe를 사용하여 요로계 감염 환자들로부터 분리한 wild type 대장균들의 DNA에 대하여 hemolysin gene의 상동성을 조사하였는 바 8개의 probe는 거의 모든 hemolysin 생산 wild type에 대하여 positive hybridization signal을 보여주었고 HA484는 28.3%, HA661은 71.7%의 positive signal을 나타내었다. 이는 요로계 감염 대장균들의 hemolysin gene의 상동성이 매우 높은 것을 의미한다. 또한J96 hemolysin에 대한 12개의 MAB은 모두 wild type 대장균들이 분비하는 90% 이상의 균주에 대하여 양성 immunoblotting을 나타내었다. 특히 J96 hemolysin의 functional site를 가장 강력하게 block할 수 있는 monoclonal antibody MAB132가 모든 wild type으로부터 분리된 hemolysin의 function을 중화시킬 수 있는 결과는 J96의 cloned hemolysin product를 vaccine으로 사용할 수 있는 가능성을 증대시키는 결과라고 할 수 있다. This work was performed to investigate the possibility of using J96 hemolysin(Hly, Hly A) vaccine against urinary tract infecting Escherichia coli. Based on the known sequence of J96 hemolysin which was originally isolated from a pyelonephritis patient, ten 20-mer oligonucleotide probes were synthesized. Radioactive labelled 8 probes showed positive colony blots against most of the hemolysin producing wild type E. coli, while HA484 and HA661 showed 28.3, 71.7% positive blots, respectively. This result means that hemolysin genes are highly conserved. Also, 12 anti-Hly MABs(monoclonal antibodies) showed more than 90% positive immunoblots against secreted hemolysin from wild type E. coli. Especially, the result that MAB132 neutralized hemolysin from all of the wild type E. coli augments the idea that hemolysin will be effective as a vaccine.
Kim, Ji Yeun,Kwon, Jung Hyun,Ahn, So Hyun,Lee, Sang Il,Han, Young Shin,Choi, Young Ok,Lee, Soo Young,Ahn, Kang Mo,Ji, Geun Eog Blackwell Publishing Ltd 2010 Pediatric allergy and immunology Vol.21 No.2
<P>Kim JY, Kwon JH, Ahn SH, Lee SI, Han YS, Choi YO, Lee SY, Ahn KM, Ji GE. Effect of probiotic mix (<I>Bifidobacterium bifidum, Bifidobacterium lactis, Lactobacillus acidophilus</I>) in the primary prevention of eczema: a double-blind, randomized, placebo-controlled trial.Pediatr Allergy Immunol 2010: 21: e386–e393.© 2009 John Wiley & Sons A/S</P><P>Controversy exists regarding the preventive effect of probiotics on the development of eczema or atopic dermatitis. We investigated whether supplementation of probiotics prevents the development of eczema in infants at high risk. In a randomized, double-blind, placebo-controlled trial, 112 pregnant women with a family history of allergic diseases received a once-daily supplement, either a mixture of <I>Bifidobacterium bifidum</I> BGN4, <I>B. lactis</I> AD011, and <I>Lactobacillus acidophilus</I> AD031, or placebo, starting at 4–8 wks before delivery and continuing until 6 months after delivery. Infants were exclusively breast-fed during the first 3 months, and were subsequently fed with breastmilk or cow’s milk formula from 4 to 6 months of age. Clinical symptoms of the infants were monitored until 1 yr of age, when the total and specific IgE against common food allergens were measured. A total of 68 infants completed the study. The prevalence of eczema at 1 yr in the probiotic group was significantly lower than in the placebo group (18.2% vs. 40.0%, p = 0.048). The cumulative incidence of eczema during the first 12 months was reduced significantly in probiotic group (36.4% vs. 62.9%, p = 0.029); however, there was no difference in serum total IgE level or the sensitization against food allergens between the two groups. Prenatal and postnatal supplementation with a mixture of <I>B. bifidum</I> BGN4, <I>B. lactis</I> AD011, and <I>L. acidophilus</I> AD031 is an effective approach in preventing the development of eczema in infants at high risk of allergy during the first year of life.</P>